Agios Pharmaceuticals (AGIO) Amortization of Deferred Charges (2019 - 2021)

Agios Pharmaceuticals has reported Amortization of Deferred Charges for 3 years, with the latest figure at $2.4 million in Q3 2021.

• For the quarter ending Q3 2021, Amortization of Deferred Charges rose 5.01% year-over-year to $2.4 million; the trailing twelve-month figure through Sep 2021 stood at $9.4 million (up 5.66% YoY), and the FY2019 full-year result was $8.5 million, changed N/A from the prior year.
• Amortization of Deferred Charges for Q3 2021 stood at $2.4 million, up from $2.3 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.4 million in Q1 2021, with the low at $2.1 million in Q1 2019.
• Historically, Amortization of Deferred Charges has averaged $2.2 million across 3 years, with a median of $2.2 million in 2020.
• The largest YoY upside for Amortization of Deferred Charges was 9.71% in 2021 against a maximum downside of 4.97% in 2021.
• Agios Pharmaceuticals' Amortization of Deferred Charges stood at $2.2 million in 2019, then advanced by 2.97% to $2.3 million in 2020, then rose by 5.01% to $2.4 million in 2021.
• The last three Amortization of Deferred Charges figures came in at $2.4 million (Q3 2021), $2.3 million (Q2 2021), and $2.4 million (Q1 2021), per Business Quant data.